A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Amylyx Pharmaceuticals, Inc.
AMLX
$1.7B
Mkt Cap
$18.41
+4.66%
Amylyx Pharmaceuticals, Inc. (AMLX) has a 5-year average return on invested capital (ROIC) of -32.8%. This is below average and may indicate limited pricing power.
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $2.0B. It is classified as a mid-cap stock.
Amylyx Pharmaceuticals, Inc. (AMLX) does not currently pay a regular dividend.
Amylyx Pharmaceuticals, Inc. (AMLX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Amylyx Pharmaceuticals, Inc. (AMLX) generated $-123 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Amylyx Pharmaceuticals, Inc. (AMLX) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Amylyx Pharmaceuticals, Inc. (AMLX) reported earnings per share (EPS) of $-1.53 in its most recent fiscal year.
Amylyx Pharmaceuticals, Inc. (also referred to as Amylyx, we, our or us) is a clinical-stage pharmaceutical company with a mission to develop and advance novel therapies for communities with high unmet medical needs. We have preclinical and clinical development programs underway in endocrine conditions and neurodegenerative diseases. We are advancing a pipeline in which we have matched investigational therapies with diseases for which we believe these therapies can make the greatest impact, based on well-defined mechanistic rationales, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality. Our current pipeline is represented in the table below. Our lead investigational asset is avexitide, a first-in-class glucagon-like peptide-1, or GLP-1, receptor antagonist. Avexitide has been evaluated as a treatment for PBH and congenital hyperinsulinism, or Congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. The U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | 381M | - | - |
| Net Income | -150M | -145M | -302M | 49M | -198M | -88M |
| EPS | $-1.45 | $-1.53 | $-4.43 | $0.70 | $-3.39 | $-13.35 |
| Free Cash Flow | 0 | -123M | -168M | 11M | -182M | -75M |
| ROIC | -42.9% | -61.6% | -100.9% | 117.4% | -40.6% | -78.3% |
| Gross Margin | - | - | - | 93.3% | - | - |
| Debt/Equity | 0.00 | 0.02 | 0.01 | 0.01 | 0.02 | -0.12 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -159M | -153M | -315M | 39M | -201M | -83M |
| Operating Margin | 0.0% | - | - | 10.2% | - | - |
| ROE | -55.0% | -61.6% | -100.9% | 12.7% | -209.4% | 80.7% |
| Shares Outstanding | 111M | 95M | 68M | 70M | 59M | 7M |
| Metric | ||||||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | N/A | N/A | 381M | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | 93.3% | N/A | N/A | N/A |
| R&D | 44M | 93M | 128M | 104M | 90M | 96M |
| SG&A | 39M | 127M | 188M | 114M | 63M | 63M |
| EBIT | -83M | -201M | 39M | -315M | -153M | -159M |
| Op. Margin | N/A | N/A | 10.2% | N/A | N/A | 0.0% |
| Net Income | -88M | -198M | 49M | -302M | -145M | -150M |
| Net Margin | N/A | N/A | 12.9% | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 24M | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -78.3% | -40.6% | 117.4% | -100.9% | -61.6% | -42.9% |
| ROE | 80.7% | -209.4% | 12.7% | -100.9% | -61.6% | -55.0% |
| ROA | -141.2% | -79.8% | 10.8% | -84.9% | -55.0% | -51.1% |
| Cash Flow | ||||||
| Op. Cash Flow | -75M | -180M | 12M | -168M | -123M | -120M |
| Free Cash Flow | -75M | -182M | 11M | -168M | -123M | 0 |
| Owner Earnings | -78M | -202M | -27M | -202M | -153M | -149M |
| CapEx | 353K | 2.5M | 1.2M | 157K | 138K | 0 |
| Maint. CapEx | 53K | 540K | 1.6M | 1.4M | 1.6M | 1.5M |
| Growth CapEx | 300K | 2.0M | 0 | 0 | 0 | 0 |
| D&A | 53K | 540K | 1.6M | 1.4M | 1.6M | 1.5M |
| CapEx/OCF | N/A | N/A | 10.4% | N/A | N/A | 0.0% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 3.1M | 22M | 37M | 33M | 28M | 27M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | N/A | -341M | -367M | -175M | -311M | -280M |
| Cash & Equiv. | 50M | 63M | 170M | 77M | 227M | 280M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.12 | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 |
| Interest Coverage | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | -151M | 341M | 433M | 165M | 305M | 273M |
| Total Assets | 106M | 391M | 517M | 194M | 333M | 294M |
| Total Liabilities | 17M | 51M | 84M | 29M | 27M | 20M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -156M | -354M | -305M | -607M | -751M | -793M |
| Working Capital | 88M | 336M | 383M | 161M | 301M | 269M |
| Current Assets | 105M | 382M | 465M | 189M | 324M | 285M |
| Current Liabilities | 17M | 47M | 82M | 28M | 23M | 16M |
| Per Share Data | ||||||
| EPS | -13.35 | -3.39 | 0.70 | -4.43 | -1.53 | -1.45 |
| Owner EPS | -11.84 | -3.45 | -0.38 | -2.97 | -1.61 | -1.34 |
| Book Value | -22.95 | 5.82 | 6.16 | 2.42 | 3.23 | 2.46 |
| Cash Flow/Share | -11.36 | -3.07 | 0.17 | -2.46 | -1.30 | -1.34 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 6.6M | 58.5M | 70.4M | 68.1M | 94.6M | 111.0M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | 21.1 | N/A | N/A | -12.7 |
| P/FCF | N/A | N/A | 97.2 | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 6.0 | 2.4 | 1.6 | 3.8 | 7.5 |
| Price/Sales | N/A | N/A | 4.6 | N/A | N/A | N/A |
| FCF Yield | N/A | -8.9% | 1.0% | -63.7% | -10.6% | N/A |
| Market Cap | N/A | 2.0B | 1.0B | 264M | 1.2B | 2.0B |
| Avg. Price | N/A | 23.67 | 24.68 | 5.47 | 7.86 | 18.41 |
| Year-End Price | N/A | 34.94 | 14.75 | 3.87 | 12.33 | 18.41 |
Amylyx Pharmaceuticals, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 93.3%.
Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity (ROE) of -61.6%. A negative ROE may indicate losses or negative equity.
Amylyx Pharmaceuticals, Inc. (AMLX) has a 5-year average gross margin of 93.3%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Amylyx Pharmaceuticals, Inc. (AMLX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Amylyx Pharmaceuticals, Inc. (AMLX) has a book value per share of $3.23, based on its most recent annual SEC filing.